# Chembio Historical Financial Ratios

CEMI | Stock | ## USD 0.86 0.01 1.18% |

Chembio Diagnostics is presently reporting on over 71 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Long Term Debt to Equity of 0.56, Calculated Tax Rate of 46.46 or PPandE Turnover of 5.55 will help investors to properly organize and evaluate Chembio Diagnostics financial condition quickly. Financial Statement Analysis is way more than just reviewing and evaluating Chembio Diagnostics prevailing accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Chembio Diagnostics is a good buy for the upcoming year.

Continue to Trending Equities.Chembio |

## About Chembio Financial Ratios Analysis

Chembio DiagnosticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Chembio Diagnostics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Chembio financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Chembio Diagnostics history.

## Chembio Diagnostics Financial Ratios Chart

Chembio Diagnostics financial ratios usually calculated using numerical values taken directly from Chembio Diagnostics financial statements such as income statements or balance sheets. They help investors to obtain meaningful information about Chembio Diagnostics. Most financial ratios help to conduct quantitative analysis to assess vital information about the company's valuation as well as profitability and liquidity indicators such as leverage, growth, profit margins, and different types of rates of return.

Chembio Diagnostics Calculated Tax Rate is most likely to increase significantly in the upcoming years. The last year's value of Calculated Tax Rate was reported at 43.06. The current PPandE Turnover is estimated to increase to 5.55, while Receivables Turnover is projected to decrease to 6.10. Add Fundamental

## Return on Average Assets

Return on assets measures how profitable a company is Net Income Common Stock relative to its total assets [AssetsAvg].## Return on Average Equity

Return on equity measures a corporation's profitability by calculating the amount of Net Income Common Stock returned as a percentage of [EquityAvg].## Return on Sales

Return on Sales is a ratio to evaluate a company's operational efficiency; calculated by dividing Earning Before Interest and Taxes EBIT by Revenues. ROS is often a component of DuPont ROE analysis.Most ratios from Chembio Diagnostics fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Chembio Diagnostics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Continue to Trending Equities.Chembio Diagnostics Calculated Tax Rate is most likely to increase significantly in the upcoming years. The last year's value of Calculated Tax Rate was reported at 43.06. The current PPandE Turnover is estimated to increase to 5.55, while Receivables Turnover is projected to decrease to 6.10.

2021 | 2022 (projected) | |

Long Term Debt to Equity | 0.52 | 0.56 |

Interest Coverage | 825.06 | 890.19 |

## Chembio Diagnostics fundamentals Correlations

**Click cells**to compare fundamentals

## Chembio Diagnostics Account Relationship Matchups

### High Positive Relationship

### High Negative Relationship

## Chembio Diagnostics fundamentals Accounts

2017 | 2018 | 2019 | 2020 | 2021 | 2022 (projected) | ||

PPandE Turnover | 13.27 | 13.97 | 7.64 | 4.3 | 5.41 | 5.55 | |

Receivables Turnover | 8.78 | 7.06 | 6.25 | 9.2 | 6.45 | 6.1 | |

Inventory Turnover | 3.33 | 3.49 | 2.57 | 2.16 | 2.71 | 3.81 | |

Accounts Payable Turnover | 16.38 | 13.06 | 10.19 | 7.3 | 7.1 | 7.28 | |

Accrued Expenses Turnover | 15.36 | 17.5 | 14.83 | 9.67 | 9.86 | 12.83 | |

Operating Margin | (26.99) | (23.89) | (38.67) | (71.25) | (64.94) | (66.65) | |

Cash and Equivalents Turnover | 2.24 | 3.35 | 4.1 | 1.57 | 1.84 | 1.89 | |

Return on Investment | (42.72) | (34.05) | (35.18) | (52.42) | (62.44) | (64.08) | |

Cash Flow Per Share | (0.41) | (0.69) | (0.51) | (0.93) | (1.03) | (1.05) | |

Revenue to Assets | 1.45 | 0.82 | 0.62 | 0.5 | 0.65 | 0.97 | |

Total Assets Per Share | 1.35 | 2.38 | 3.14 | 3.21 | 2.43 | 2.22 | |

Net Current Assets as percentage of Total Assets | 46.69 | 53.61 | 46.26 | 42.2 | 54.01 | 49.52 | |

Asset Turnover | 1.26 | 1.09 | 0.69 | 0.49 | 0.72 | 0.84 | |

Book Value per Share | 1.62 | 1.06 | 2.31 | 1.42 | 1.46 | 1.41 | |

Current Ratio | 3.51 | 4.36 | 5.0 | 3.22 | 3.61 | 4.17 | |

EBITDA Margin | (0.22) | (0.2) | (0.33) | (0.63) | (0.59) | (0.6) | |

Earnings per Basic Share | (0.52) | (0.54) | (0.81) | (1.34) | (1.4) | (1.44) | |

Earnings per Diluted Share | (0.52) | (0.54) | (0.81) | (1.34) | (1.4) | (1.44) | |

Earnings per Basic Share USD | (0.52) | (0.54) | (0.81) | (1.34) | (1.4) | (1.44) | |

Enterprise Value over EBIT | (15.0) | (11.0) | (6.0) | (4.0) | (1.0) | (1.08) | |

Enterprise Value over EBITDA | (19.15) | (12.83) | (7.29) | (4.53) | (0.86) | (0.93) | |

Free Cash Flow per Share | (0.49) | (0.92) | (0.74) | (1.2) | (1.35) | (1.38) | |

Gross Margin | 0.47 | 0.46 | 0.35 | 0.27 | 0.28 | 0.31 | |

Profit Margin | (0.26) | (0.23) | (0.4) | (0.79) | (0.71) | (0.73) | |

Price to Book Value | 7.72 | 2.92 | 3.33 | 3.45 | 1.0 | 1.03 | |

Price to Earnings Ratio | (15.77) | (10.48) | (5.63) | (3.54) | (0.81) | (0.83) | |

Price to Sales Ratio | 4.2 | 2.36 | 2.24 | 2.79 | 0.58 | 0.59 | |

Return on Average Assets | (0.33) | (0.25) | (0.27) | (0.39) | (0.51) | (0.53) | |

Return on Average Equity | (0.42) | (0.32) | (0.5) | (0.86) | (1.12) | (1.16) | |

Return on Sales | (0.27) | (0.23) | (0.39) | (0.71) | (0.65) | (0.67) | |

Sales per Share | 1.95 | 2.4 | 2.03 | 1.7 | 1.97 | 2.04 | |

Tangible Assets Book Value per Share | 1.09 | 2.22 | 2.71 | 2.9 | 2.89 | 2.85 |

## Be your own money manager

Our tools can tell you how much better you can do entering a position in Chembio Diagnostics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.## Did you try this?

### Run Idea Optimizer Now

## Idea OptimizerUse advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |

All Next | Launch Module |

## Pair Trading with Chembio Diagnostics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Chembio Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Chembio Diagnostics will appreciate offsetting losses from the drop in the long position's value.### Moving together with Chembio Diagnostics

0.71 | AXDX | Accelerate Diagnosti | Earnings Call Today | PairCorr |

### Moving against Chembio Diagnostics

0.6 | ADMT | Adm Tronics Unlimited | Earnings Call This Week | PairCorr | |||

0.56 | ALRN | Aileron Therapeutics | Earnings Call Today | PairCorr | |||

0.55 | GTH | Genetron Holdings | Earnings Call This Week | PairCorr | |||

0.54 | ABC | Amerisourcebergen Corp | Fiscal Year End 3rd of November 2022 | PairCorr |

The ability to find closely correlated positions to Chembio Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Chembio Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Chembio Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Chembio Diagnostics to buy it.

The correlation of Chembio Diagnostics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Chembio Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Chembio Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Chembio Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Continue to Trending Equities. Note that the Chembio Diagnostics information on this page should be used as a complementary analysis to other Chembio Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

## Complementary Tools for Chembio Stock analysis

When running Chembio Diagnostics price analysis, check to measure Chembio Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chembio Diagnostics is operating at the current time. Most of Chembio Diagnostics' value examination focuses on studying past and present price action to predict the probability of Chembio Diagnostics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Chembio Diagnostics' price. Additionally, you may evaluate how the addition of Chembio Diagnostics to your portfolios can decrease your overall portfolio volatility.

Crypto CorrelationsUse cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | Go | |

Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios | Go | |

Probability Of BankruptcyGet analysis of equity chance of financial distress in the next 2 years | Go | |

CEO DirectoryScreen CEOs from public companies around the world | Go | |

Bond DirectoryFind actively traded corporate debentures issued by US companies | Go | |

Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk | Go | |

Insider ScreenerFind insiders across different sectors to evaluate their impact on performance | Go | |

Portfolio DiagnosticsUse generated alerts and portfolio events aggregator to diagnose current holdings | Go |

Is Chembio Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chembio Diagnostics. If investors know Chembio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chembio Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Market Capitalization 26 M | Quarterly Revenue Growth YOY 0.42 | Return On Assets -0.3 | Return On Equity -2.06 |

The market value of Chembio Diagnostics is measured differently than its book value, which is the value of Chembio that is recorded on the company's balance sheet. Investors also form their own opinion of Chembio Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Chembio Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chembio Diagnostics' market value can be influenced by many factors that don't directly affect Chembio Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Chembio Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine Chembio Diagnostics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chembio Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.